[1]
T. P. Mega e R. M. da Silva, “Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system”, Rev. saúde pública, vol. 57, nº 1, p. 41, jul. 2023, doi: 10.11606/s1518-8787.2023057004280.